Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma
This clinical trial compares and contrasts lymph node mapping using indocyanine green (IC-GREEN), isosulfan blue (ISB), and TSC and Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC).
Study participants with malignant melanoma will undergo all 3 evaluations to assess the extent of the spread of the melanoma.
Stanford is currently not accepting patients for this trial.
Intervention(s):
- drug: Isosulfan blue (ISB)
- diagnostic test: Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC)
- drug: indocyanine green solution
Eligibility
Inclusion Criteria:
- Ability to understand and willingness to sign informed consent document
- Signed written informed consent
- Malignant melanoma (MM) undergoing sentinel lymph node biopsy (SNLB)
- 18 years of age or older
- Complete blood count (CBC) and metabolic panel within 6 months
Exclusion Criteria:
- History of hepatic or renal failure
- Allergy to iodine containing products
- Pregnant or may be pregnant
- Psychiatric or addictive disorders that in the opinion of the research team, may not
be able to meet study requirements
- Undergoing dialysis
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Ralph S. Greco
650-736-1355
Not Recruiting
Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation, mobile application development, and pharmaceutical trials.
Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.
